NCT01964183已完成4 期
Post-Marketing Study of Mirabegron - A Pharmacokinetic Study to Assess Drug-Drug Interaction Between Mirabegron and Tolterodine -
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Plasma concentration of unchanged tolterodine
研究概览
简要总结
To assess the effect of multiple doses of mirabegron to postmenopausal adult female subjects on the pharmacokinetics (PK) of tolterodine and its metabolites.
In addition, the safety of these products will be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subjects of two years after menopause
- •Body weight (at screening) ≥ 40.0 kg and < 70.0 kg
- •Body mass index (BMI) (at screening) ≥ 17.6 kg/m2 and < 26.4 kg/m2
- •Healthy, as judged by the investigator/sub-investigator based on medical history and the results of physical examination (subjective symptoms and objective findings) and all tests obtained at screening and during the period from hospital admission (at single dosing phase) to immediately before study medication.
排除标准
- •Received or scheduled to receive any investigational drugs in other clinical trials, post-marketing studies, or clinical studies within 120 days before the screening or during the period from the screening to hospitalization (Day -2).
- •Donated or scheduled to donate 400 mL of whole blood within 90 days before the screening or during the period from the screening to hospitalization (Day -2), 200 mL of whole blood within 30 days before the screening or during the period from the screening to hospitalization (Day -2), or blood components within 14 days before the screening or during the period from the screening to hospitalization (Day -2).
- •Any deviation of the laboratory tests at screening or hospitalization (Day -2).
- •A deviation from the normal range of blood pressure, pulse rae, or body temperature at screening or hospitalization (Day -2) Supine blood pressure: Systolic blood pressure: ≥90 mmHg, ≤140 mmHg, Diastolic blood pressure: ≥40 mmHg, ≤90 mmHg Supine pulse rate; ≥40 bpm, ≤99 bpm Axillary body temperature; ≥35.0°C, ≤37.0°C
- •History of drug allergies
- •Upper gastrointestinal disease (e.g., nausea, vomiting, and stomachache) within 7 days before hospitalization (Day -2)
- •Concurrent or previous hepatic disease (e.g., viral hepatitis, drug-induced liver injury, and hepatic impairment)
- •Concurrent or previous heart disease (e.g., congestive heart failure, angina pectoris, and arrhythmia requiring treatment)
- •Concurrent or previous GI disease (e.g., ileus paralytic, gastric atony, intestinal atony, colitis ulcerative, peptic ulcer and gastroesophageal reflux esophagitis; except for a history of appendicitis).
- •Concurrent or previous renal disease (e.g., acute renal failure, glomerulonephritis, and interstitial nephritis)
- •Concurrent or previous endocrine disease (e.g., hyperthyroidism and blood growth hormone abnormal)
- •Concurrent or previous cerebrovascular disorder (e.g., cerebral infarction)
- •Previous use of mirabegron or tolterodine
- •Excessive smoking or drinking habit
研究组 & 干预措施
treatment group
Experimental
干预措施: tolterodine (Drug)
treatment group
Experimental
干预措施: mirabegron (Drug)
结局指标
主要结局
Plasma concentration of unchanged tolterodine
时间窗: Day 7, Day 14
Plasma concentration of unchanged mirabegron
时间窗: Day 14
次要结局
- Plasma concentration of tolterodine metabolites (5-hydroxymethyl tolterodine; 5-HMT)(Day 7, Day 14)
- Safety assessed by the incidence of adverse events, vital signs, clinical labo-tests, and 12-lead ECG(Day -2, Day 8, Day 15, Day 22)
研究者
相似试验
已完成
1 期
To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly FemalesPharmacokineticsHealthy SubjectsNCT01478503Astellas Pharma Inc96
已完成
4 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)Overactive Bladder (OAB)NCT02216214Astellas Pharma Global Development, Inc.888
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.Urologic DiseasesUrinary Bladder, OveractiveUrinary Bladder DiseasesNCT01638000Astellas Pharma Europe Ltd.1,887
已完成
4 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)Overactive BladderBenign Prostatic HyperplasiaNCT02757768Astellas Pharma Global Development, Inc.715
已完成
1 期
A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive PillHealthy VolunteersPharmacokinetics of MirabegronNCT01297179Astellas Pharma Inc30